Next, we wanted to determine whether targeting ERα could block the metabolic and proliferative effects of estrogens in PCa by using ERα-positive breast cancer drugs, such as the pure anti-estrogen fulvestrant and SERMs (tamoxifen, raloxifene, and toremifene). This evidence concerns the gene ESR1 and posterior cortical atrophy.